{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:41:54Z","timestamp":1761514914967,"version":"3.37.3"},"reference-count":24,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Venous thromboembolism (VTE) is a life-threatening complication observed among patients with sickle cell disease (SCD) and also among those with severe COVID-19 infection. Although prior studies show that patients with SCD are at risk of severe COVID-19 illness, it remains unclear if COVID-19 infection further increases VTE risk for this population. We hypothesized that patients with SCD hospitalized for COVID-19 would have higher VTE rates than those hospitalized for other causes. Using electronic health record data from a multisite research network, TriNetX, we identified 2 groups of patients with SCD hospitalized during 2020: (1) with COVID-19 and (2) without COVID-19. We compared VTE rates using risk ratios estimated based on adjusted Poisson regression model with log link and robust error variances. Of the 281 SCD patients hospitalized with COVID-19 and 4873 SCD patients hospitalized without COVID-19 , 35 (12.46%) and 418 (8.58%) had incident VTE within 6 months of the index hospitalization respectively. After adjusting for differences in baseline characteristics, no significant differences in VTE rates within 6 months were found between the 2 groups (adjusted relative risk, 1.06 [95% confidence interval, 0.79-1.41]). These data suggest that hospitalization with COVID-19 does not further increase VTE risk in patients with SCD.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007219","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T20:43:08Z","timestamp":1656362588000},"page":"4408-4412","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["COVID-19 and venous thromboembolism risk in patients with sickle cell disease"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1270-8132","authenticated-orcid":false,"given":"Ashima","family":"Singh","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Section of Hematology\/Oncology\/Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9396-0470","authenticated-orcid":false,"given":"Amanda M.","family":"Brandow","sequence":"additional","affiliation":[{"name":"1Department of Pediatrics, Section of Hematology\/Oncology\/Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6383-7172","authenticated-orcid":false,"given":"Ted","family":"Wun","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, UC Davis School of Medicine, Sacramento, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4146-0703","authenticated-orcid":false,"given":"Arun S.","family":"Shet","sequence":"additional","affiliation":[{"name":"3Laboratory of Sickle Thrombosis and Vascular Biology, Sickle Cell Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,8,1]]},"reference":[{"issue":"8","key":"2022080115254930000_B1","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3390\/jcm9082467","article-title":"Prevention of venous thromboembolism in 2020 and beyond","volume":"9","author":"Nicholson","year":"2020","journal-title":"J Clin Med."},{"key":"2022080115254930000_B2","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","article-title":"Venous thromboembolism: a public health concern","volume":"38","author":"Beckman","year":"2010","journal-title":"Am J Prev Med."},{"issue":"1","key":"2022080115254930000_B3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/jth.12787","article-title":"Prospective study of sickle cell trait and venous thromboembolism incidence","volume":"13","author":"Folsom","year":"2015","journal-title":"J Thromb Haemost."},{"issue":"3","key":"2022080115254930000_B4","doi-asserted-by":"crossref","first-page":"e012665","DOI":"10.1136\/bmjopen-2016-012665","article-title":"Venous thromboembolism in adults screened for sickle cell trait: a population-based cohort study with nested case-control analysis","volume":"7","author":"Little","year":"2017","journal-title":"BMJ Open."},{"issue":"5","key":"2022080115254930000_B5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.amjmed.2012.12.016","article-title":"Venous thromboembolism in adults with sickle cell disease: a serious and under-recognized complication","volume":"126","author":"Naik","year":"2013","journal-title":"Am J Med."},{"issue":"2","key":"2022080115254930000_B6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.14655","article-title":"Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality","volume":"178","author":"Brunson","year":"2017","journal-title":"Br J Haematol."},{"key":"2022080115254930000_B7","doi-asserted-by":"crossref","first-page":"100639","DOI":"10.1016\/j.eclinm.2020.100639","article-title":"Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and meta-analysis","volume":"29","author":"Malas","year":"2020","journal-title":"EClinicalMedicine."},{"issue":"12","key":"2022080115254930000_B8","first-page":"e12348","article-title":"COVID-19 infection and acute pulmonary embolism in an adolescent female with sickle cell disease","volume":"12","author":"Kasinathan","year":"2020","journal-title":"Cureus."},{"issue":"6","key":"2022080115254930000_B9","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1159\/000511800","article-title":"COVID-19-associated systemic thromboembolism: a case report and review of the literature","volume":"10","author":"Mahajan","year":"2020","journal-title":"Cardiorenal Med."},{"issue":"7","key":"2022080115254930000_B10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.14740\/jmc3500","article-title":"A case of COVID-19 complicated by venous thromboembolism despite being on prophylactic anticoagulation","volume":"11","author":"Rout","year":"2020","journal-title":"J Med Cases."},{"key":"2022080115254930000_B11","first-page":"101263","article-title":"Acute high-risk pulmonary embolism requiring thrombolytic therapy in a COVID-19 pneumonia patient despite intermediate dosing deep vein thromboprophylaxis","volume":"31","author":"Salam","year":"2020","journal-title":"Respir Med Case Rep."},{"issue":"10","key":"2022080115254930000_B12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1136\/thoraxjnl-2020-215383","article-title":"Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis","volume":"76","author":"Tan","year":"2021","journal-title":"Thorax."},{"issue":"1","key":"2022080115254930000_B13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s13054-020-03077-0","article-title":"The unique characteristics of COVID-19 coagulopathy","volume":"24","author":"Iba","year":"2020","journal-title":"Crit Care."},{"issue":"7","key":"2022080115254930000_B14","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/bloodadvances.2020003741","article-title":"COVID-19 in individuals with sickle cell disease\/trait compared with other Black individuals","volume":"5","author":"Singh","year":"2021","journal-title":"Blood Adv."},{"issue":"10","key":"2022080115254930000_B15","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.3201\/eid2610.202792","article-title":"Coronavirus disease among persons with sickle cell disease, United States, March 20-May 21, 2020","volume":"26","author":"Panepinto","year":"2020","journal-title":"Emerg Infect Dis."},{"issue":"10","key":"2022080115254930000_B16","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.3324\/haematol.2019.239350","article-title":"The molecular basis for the prothrombotic state in sickle cell disease","volume":"105","author":"Shet","year":"2020","journal-title":"Haematologica."},{"author":"TriNetX","key":"2022080115254930000_B17"},{"issue":"11","key":"2022080115254930000_B18","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/bloodadvances.2018017541","article-title":"Identification of patients with hemoglobin SS\/S\u03b20 thalassemia disease and pain crises within electronic health records","volume":"2","author":"Singh","year":"2018","journal-title":"Blood Adv."},{"issue":"3","key":"2022080115254930000_B19","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.acap.2016.12.005","article-title":"Identification and validation of a sickle cell disease cohort within electronic health records","volume":"17","author":"Michalik","year":"2017","journal-title":"Acad Pediatr."},{"issue":"12","key":"2022080115254930000_B20","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/MLR.0000000000000524","article-title":"Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study","volume":"55","author":"Fang","year":"2017","journal-title":"Med Care."},{"issue":"2","key":"2022080115254930000_B21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11239-019-01885-y","article-title":"Assessing the accuracy of ICD-10 codes for identifying acute thromboembolic events among patients receiving anticoagulation therapy","volume":"48","author":"Lawrence","year":"2019","journal-title":"J Thromb Thrombolysis."},{"issue":"8","key":"2022080115254930000_B22","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ajh.25508","article-title":"High incidence of venous thromboembolism recurrence in patients with sickle cell disease","volume":"94","author":"Brunson","year":"2019","journal-title":"Am J Hematol."},{"issue":"23","key":"2022080115254930000_B23","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation","volume":"135","author":"Connors","year":"2020","journal-title":"Blood."},{"author":"National Institutes of Health","key":"2022080115254930000_B24"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/15\/4408\/1910869\/advancesadv2022007219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/15\/4408\/1910869\/advancesadv2022007219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T15:29:14Z","timestamp":1659367754000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/15\/4408\/485702\/COVID-19-and-venous-thromboembolism-risk-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,1]]},"references-count":24,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,8,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007219","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published":{"date-parts":[[2022,8,1]]}}}